Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

November 10, 2017: By Jon Swedien

EYLEARegeneron reported Nov. 8 that net sales of Eylea (aflibercept) in the US totaled $953 million in Q3-2017, a 12 percent increase over Q3-2016 revenues of $854 million.

Bayer commercializes Eylea outside the US. In Q3-2017, net sales of Eylea outside of the US were $564 million, compared with $471 million in the third quarter of 2016, a 20 percent increase, Regeneron said. In Q3-2017, Regeneron recognized $205 million from its share of net profit from Eylea sales outside the US, compared with $171 million in Q3-2016.

About 70 percent of Eylea sold in the US goes to treat wet age-related macular degeneration and about 25 percent goes to treat diabetic macular edema (DME), said Manisha Narasimhan, PhD, Regeneron’s head of investor relations. Narasimhan said DME represents a significant growth opportunity for Eylea because a large majority of patients are not currently using an anti-VEGF treatment.

Regeneron, based in Tarrytown, New York, posted $1.5 billion in revenues in Q3-2017, compared with $1.2 billion in Q3-2016, a 23 percent increase.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Boy, 13, is First Patient Treated Commercially with Luxturna

Wet AMD Patients Regain Vision with Patch of Stem Cell-Derived RPE Cells, Moorfields Reports

ASCRS Meeting Returns to April Date in 2018, Avoiding Scheduling Conflicts

US FDA Approves Lucentis Prefilled Syringe for Diabetic Retinopathy, Diabetic Macular Edema

FDA Accepts pSivida’s Filing for Durasert as Treatment for Posterior Segment Uveitis

Eylea Meets Primary Endpoint in Phase III Trial for Nonproliferative Diabetic Retinopathy

Bascom Palmer Receives $12 Million Gift to Establish Research Center

SemaThera Announces $2 Million Financing, Licensing Deal for DME Candidate in China, Japan

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023